All the Drug Class Drugs
5-HT3 Antagonist, Selective Antagonist of NK1 Receptors. Netupitant 300 mg, Palonosetron (hydrochloride) 0.5 mg. CAP.: 1. One 300 mg / 0.5 mg cap. should be administered approx. one h. prior to the start of each chemother. cycle. The recommend. oral dexamethasone dose should be reduced by approx. 50 % when co-admin. with this formul.
Preven.of acute & delayed nausea and vomit. assoc. with init. and repeat courses of cancer chemoth., includ., but not limited to, highly emetogenic chemother.
C/I: Hypersens., preg.
5-HT3 Antagonist. Ondansetron (as HCl dihydrate) 2 mg/ml. AMPS: 1, 5, 10, 50 x 2 ml, 4ml. Depends on indica. and age. See lit.
Adults: tmt of nausea and vomit. induced by cytotoxic chemother. and radiother.,prevent. and tmt of post-operative nausea and vomit.(PONV). Child: tmt of chemotherapy-induced nausea and vomit. (CINV) in children aged ≥6 months and for prevent. and tmt of PONV in children aged ≥ 1month.
C/I: Hypersens., concom. use with apomorphine.
5-HT3 Antagonist. Ondansetron 4 mg, 8 mg. F.C.TABS.: 3, 4, 6, 7, 10, 14, 15, 20, 28, 30,
40, 49, 50, 60, 90, 100, 200, 300, 500.
8 mg ×2/d.
Manag. of nausea and vomit. induced by
cytotoxic chemother. and radiother.
Preven. and tmt. of postoperat. nausea
and vomit. in adults.
C/I: Hypersens. Concom. use with
5-HT3 Antagonist. Ondansetron (HCl dihydrate) 2 mg/ml. AMPS (sol. for inject.): 5 x 2 ml, 4 ml. 8
mg as slow I.V./I.M. inject. immed. bef.
tmt. See lit.
Manage. naus./vomit. induced by
cytotox. chemother./radiother., prevent./
tmt. post-op. naus./vomit. in adults and
child 2 yrs and older.
C/I: Hypersens., pregn., lact. See lit.
5-HT3 Antagonist. Palonosetron (as HCl) 0.25 mg/vial. VIALS (sol. for inject.): 1 x 5 ml. 0.25 mg
I.V. as single dose over 30 secs. approx.
30 mins. bef. start chemo. Repeat.
dose within 7-day interval not
recommend. Not to be mixed with
other drugs. Flush infus. line with
normal saline bef. and aft. admin.
Elderly/ren./hep. impair: No dose
Prevent chemo.-induced naus. and